DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety

The incretin system has proven to be a new source of glucose-lowering drugs. Glucon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are the incretins which are degraded by dipeptidyl peptidase-4 (DPP-4). GLP-1 is the major relevant incretin in type 2 diabetes, GIP has littl...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: de Valk, Harold W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: SBDR - Society for Biomedical Diabetes Research 2007
Pynciau:
Editorial
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2174059/
https://ncbi.nlm.nih.gov/pubmed/18084670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1900/RDS.2007.4.126
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg